Monitorización farmacocinética de antiepilépticos

Johannessen, 2003, Therapeutic drug monitoring of the newer antiepileptic drugs, Ther Drug Monit, 25, 347, 10.1097/00007691-200306000-00016

Eadi, 2001, Therapeutic drug monitoring of antiepileptic drugs, Br J Clin Pharmacol, 52, S11, 10.1111/j.1365-2125.2001.00394.x

Armijo, 2002, Monitorización de los niveles séricos de los nuevos antiepilépticos, Rev Neurol, 35, S116

Patsalos, 2008, Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring:A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies, Epilepsia, 49, 1239, 10.1111/j.1528-1167.2008.01561.x

Lacerda, 2006, Optimizing therapy of seizures in patients with renal or hepatic dysfunction, Neurology, 67, S28

2008

Neels, 2004, Therapeutic drug monitoring of old and newer anti-epileptic drugs, Clin Chem Lab Med, 42, 1228, 10.1515/CCLM.2004.245

Loughnan, 1977, Pharmacokinetic observations of phenytoin disposition in the newborn and young infant, Arch Dis Child, 52, 302, 10.1136/adc.52.4.302

Morris, 1998, Lamotrigine and therapeutic drug monitoring:retrospective survey following the introduction of a routine service, Br J Clin Pharmacol, 46, 547, 10.1046/j.1365-2125.1998.00835.x

Schapel, 1996, Combination vigabatrin and lamotrigine therapy for intractable epilepsy, Seizure, 5, 51, 10.1016/S1059-1311(96)80063-X

Petrenaite, 2005, Individual changes in lamotrigine plasma concentrations during pregnancy, Epilepsy research, 65, 185, 10.1016/j.eplepsyres.2005.06.004

Leppik IE, Rarick JO, Walczak TS, Tran TE, White JR, Gumnit RJ (Research, MINCEP Epilepsy Care, Minneapolis, MN). Effective levetiracetam doses and serum concentrations: age effects. Epilepsia. 2002. 43 Suppl 7:240.

Lancelin, 2007, Ther Drug Monitor, 29, 576, 10.1097/FTD.0b013e318157032d

May, 2003, Clinical pharmacokinetics of oxcarbazepine, Clin Pharmacokinet, 42, 1023, 10.2165/00003088-200342120-00002

Armijo, 2005, 10-hydroycarbazepine serum concentration-to-oxcarbazepine dose ratio. Influence of age and concomitant antiepileptics drugs, Ther Drug Monit, 27, 199, 10.1097/01.ftd.0000155342.93489.fd

Sapin, 1988, Efficacy of primidone for seizure control in neonates and young infants, Ped Neurol, 292, 10.1016/0887-8994(88)90068-9

Malagón-Valdez, 2004, Nuevos antiepilépticos:indicaciones y efectos colaterales, Rev Neurol, 39, 570

Hermida, 2005, A theoretical method for normalizing total serum valproic acid concentration in hypoalbuminemic patients, J Pharmacol Sci, 97, 489, 10.1254/jphs.FPE04007X

Pennell, 2003, Antiepileptic drug pharmacokinetics during pregnancy and lactation, Neurol, 61, S35

Warner, 1998, Standards of laboratory practice:antiepileptic drug monitoring, Clin Chem, 44, 1085, 10.1093/clinchem/44.5.1085

1997

Lewis D, Davis G (Pharmacy Services. University of Kentucky HealthCare). Clinical Pharmacokinetics Service & anticoagulation guidelines; 2008.

Anderson, 2008, Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs, Ther Drug Monit, 30, 173, 10.1097/FTD.0b013e318167d11b

Affolter, 2003, Appropriateness of serum level determinations of antiepileptic drugs, Swiss Med Wkly, 133, 591

Martinavarro-Domínguez, 2002, Therapeutic drug monitoring of anticonvulsant drugs by micellar HPLC with direct injection of serum samples, Clin Chemistry, 48, 1696, 10.1093/clinchem/48.10.1696

Bugamelli, 2002, Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatography after solid-phase extraction, Analytica Chimica Acta, 472, 1, 10.1016/S0003-2670(02)00980-7

Vermeij, 2007, Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction, J Chromatogr B, 857, 40, 10.1016/j.jchromb.2007.06.023

Thormann, 2001, Therapeutic drug monitoring of antiepileptics by capillary electrophoresis: Characterization of assays via analysis of quality control sera containing 14 analytes, J Chromatogr A, 924, 429, 10.1016/S0021-9673(01)00854-8

Gupta, 2007, Development of membrane electrodes for selective determination of some antiepileptic drugs in pharmaceuticals, plasma and urine, Anal Bioanal Chem, 389, 2019, 10.1007/s00216-007-1560-0

Tsanaclis, 1997, Comparison by external quality assessment of performance of analytical systems for measurement of therapeutic drugs in serum, Ther Drug Monit, 19, 420, 10.1097/00007691-199708000-00010

Liu, 1999, Therapeutic drug concentration monitoring using saliva samples. Focus on Anticonvulsants, Clin Pharmacokinet, 36, 453, 10.2165/00003088-199936060-00006

Dasgupta, 2005, Analytic performance evaluation of a new turbidimetric immunoassay for carbamazepine on the ADVIA 1650 Analyzer:Effecto of carbamazepine 10,11-epoxide, Ther Drug Monit, 27, 31, 10.1097/00007691-200502000-00007

Al Za’Abi, 2003, Salivary free concentrations of anti.epileptic drugs:an evaluation in a routine clinical setting, Acta Neurol Belg, 103, 19

Dasgupta, 2007, Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management, Clin Chimical Acta, 377, 1, 10.1016/j.cca.2006.08.026

Warner, 1998, Standards of laboratory practice:antiepileptic drug monitoring, Clinical Chemistry, 44, 1085, 10.1093/clinchem/44.5.1085

Klotz, 1978, Disposition of VPA in patients with liver disease, Eur J Clin Pharmacol, 13, 55, 10.1007/BF00606683

1992

Padilla, 2005, Monitorización de la concentración libre de ácido valproico en un paciente posquirúrgico septicémico, Farm Hosp, 29, 215, 10.1016/S1130-6343(05)73665-5

Iwamoto, 2005, Clinical evaluation of plasma free phenytoin measurement and factors influencing its protein binding, Biopharm Drug Dispos, 27, 77, 10.1002/bdd.486

Patsalos, 2003, Clinically important drug interactions in epilepsy:interactions between antiepileptic drugs and other drugs, Lancet Neurol, 2, 473, 10.1016/S1474-4422(03)00483-6

Perucca, 2005, Clinically relevant drug interactions with antiepileptic drugs, Br J Clin Pharmacol, 61, 246, 10.1111/j.1365-2125.2005.02529.x

Patsalos, 2000, Pharmacokinetic profile of levetiracetam:toward ideal characteristics, Pharmacol Therap, 85, 77, 10.1016/S0163-7258(99)00052-2

Williams, 2006, So many studies, too few subjects:establishing functional relevance of genetic polymorphisms on pharmacokinetics, J Clin Pharmacol, 46, 258, 10.1177/0091270005283463

Klotz, 2007, The role of pharmacogenetics in the metabolism of antiepileptic drugs. Pharmacokinetic and therapeutic implications, Clin Pharmacokinet, 46, 271, 10.2165/00003088-200746040-00001